Plasmepsins as potential targets for new antimalarial therapy

Medicinal Research Reviews

Volumn 26, Issue 5, 2006, Pages 626-666

  Ersmark, Karolina ^a   Samuelsson, Bertil ^b   Hallberg, Anders ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b MEDIVIR AB   (Sweden)

Author keywords

Aspartic protease; Malaria; Plasmepsin; Plasmodium falciparum; Protease inhibitor

Indexed keywords

4 AMINOQUINOLINE; 8 AMINOQUINOLINE DERIVATIVE; ANTIMALARIAL AGENT; ARTEMETHER; ARTESUNATE; ASPARTIC PROTEINASE; ATOVAQUONE; CHLOROQUINE; DOXYCYCLINE; FANSIDAR; HALOFANTRINE; HEMOGLOBIN; HISTO ASPARTIC PROTEASE; MEFLOQUINE; PEPSTATIN; PHENANTHRENE DERIVATIVE; PLASMEPSIN I; PLASMEPSIN II; PLASMEPSIN IV; PRIMAQUINE; PROGUANIL; PROTEINASE INHIBITOR; PYRIMETHAMINE; QUININE; QUINOLINE DERIVATIVE; RO 40 4388; STATINE; SULFADOXINE; TETRACYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

DRUG MECHANISM; DRUG STRUCTURE; ERYTHROCYTE; MALARIA; PLASMODIUM FALCIPARUM; PLASMODIUM MALARIAE; PLASMODIUM OVALE; PLASMODIUM VIVAX; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIMALARIALS; ASPARTIC ENDOPEPTIDASES; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; MALARIA;

EID: 33747177314     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.20082     Document Type: Review

References (168)

1. Breman JG. The ears of the hippopotamus: Manifestations, determinants, and estimates of the malaria burden. Am J Trop Med Hyg 2001;64:1-11.
2. The World Health Report 2004. Changing history. Geneva: World Health Organization (WHO) Annex Table 2: Deaths by cause, sex and mortality stratum in WHO regions, estimates for 2002; 2004.
3. Korenromp E. Malaria incidence estimates at country level for the year 2004-proposed estimates and draft report: World Health Organization (WHO), Roll Back Malaria (RBM); 2004.
4. The World Health Report 2002. Reducing risks, promoting healthy life. Geneva: World Health Organization (WHO); 2002. p. 186-191.
5. Sachs J, Malaney P. The economic and social burden of malaria. Nature 2002;415:680-685.
6. White NJ. Malaria parasites go ape. Lancet 1993;341:793.
7. Mackintosh CL, Beeson JG, Marsh K. Clinical features and pathogenesis of severe malaria. Trends Parasitol 2004;20:597-603.
8. Alilio Martin S, Bygbjerg Ib C, Breman Joel G. Are multilateral malaria research and control programs the most successful? Lessons from the past 100 years in Africa. Am J Trop Medicine Hyg 2004;71:268-278.
9. Richie TL, Saul A. Progress and challenges for malaria vaccines. Nature 2002;415:694-701.
10. Korenromp E, Miller J, Nahlen B, Wardlaw T, Young M. World Malaria Report 2005: World Health Organization (WHO), Roll Back Malaria (RBM) Department, and the United Nations Children's Fund (UNICEF); 2005.
11. Gardner MJ, Hall N, Fung E, White O, Berriman M, Hyman RW, Carlton JM, Pain A, Nelson KE, Bowman S, Paulsen IT, James K, Eisen JA, Rutherford K, Salzberg SL et al., Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 2002;419:498-511.
12. Holt RA, Mani Subramanian G, Halpern A, Sutton GG, Charlab R, Nusskern DR, Wincker P, Clark AG, Ribeiro JMC, Wides R, Salzberg SL, Loftus B, Yandell M, Majoros WH, Rusch DB, et al. The genome sequence of the malaria mosquito Anopheles gambiae. Science 2002;298:129-149.
13. Hoffman SL, Subramanian GM, Collins FH, Venter JC. Plasmodium, human and Anopheles genomics and malaria. Nature 2002;415:702-709.
14. Young JA, Winzeler EA. Using expression information to discover new drug and vaccine targets in the malaria parasite Plasmodium falciparum. Pharmacogenomics 2005;6:17-26.
15. Greenwood D. The quinine connection. J Antimicrob Chemother 1992;30:417-427.
16. Rosenthal PJ, editor. Antimalarial chemotherapy: Mechanisms of action, resistance, and new directions in drug discovery. Totowa, New Jersey: Human Press; 2001.
17. Egan TJ. Haemozoin (malaria pigment): A unique crystalline drug target. Targets 2003;2:115-124.
18. Fitch CD. Ferriprotoporphyrin IX, phospholipids, and the antimalarial actions of quinoline drugs. Life Sci 2004;74:1957-1972.
19. Casteel DA. Antimalaria Agents. In: Wolff ME, editor. Burger's medicinal chemistry and drug discovery. Volume 5: Therapeutic Agents. New York: John Wiley & Sons; 1997. p 3-91.
20. Tang Y, Dong Y, Wang X, Sriraghavan K, Wood JK, Vennerstrom JL. Dispiro-1,2,4-trioxane analogues of a prototype dispiro-1,2,4-trioxolane: Mechanistic comparators for artemisinin in the context of reaction pathways with Iron(II). J Org Chem 2005;70:5103-5110.
21. Gregson A, Plowe CV. Mechanisms of resistance of malaria parasites to antifolates. Pharmacol Rev 2005;57:117-145.
22. Winstanley P, Ward S, Snow R, Breckenridge A. Therapy of falciparum malaria in sub-saharan Africa: From molecule to policy. Clin Microbiol Rev 2004;17:612-637.
23. Kremsner PG, Krishna S. Antimalarial combinations. Lancet 2004;364:285-294.
24. Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR. Epidemiology of drug-resistant malaria. Lancet Infect Dis 2002;2:209-218.
25. White Nicholas J. Antimalarial drug resistance. J Clin Invest 2004;113:1084-1092.
26. Walker DJ, Pitsch JL, Peng MM, Robinson BL, Peters W, Bhisutthibhan J, Meshnick SR. Mechanisms of artemisinin resistance in the rodent malaria pathogen Plasmodium yoelii. Antimicrob Agents Chemother 2000;44:344-347.
27. Arav-Boger R, Shapiro TA. Molecular mechanisms of resistance in antimalarial chemotherapy: The unmet challenge. Annu Rev Pharmacol Toxicol 2005;45:565-585, 1 plate.
28. Zhang H, Paguio M, Roepe PD. The antimalarial drug resistance protein Plasmodium falciparum chloroquine resistance transporter binds chloroquine. Biochemistry 2004;43:8290-8296.
29. Olliaro PL, Yuthavong Y. An overview of chemotherapeutic targets for antimalarial drug discovery. Pharmacol Ther 1999;81:91-110.
30. Dominguez JN. Chemotherapeutic agents against malaria: What next after chloroquine? Curr Top Med Chem 2002;2:1173-1185.
31. Waters NC, Dow GS, Kozar MP. Antimalarial compound identification and design: Advances in the patent literature, 2000-2003. Expert Opin Ther Patents 2004;14:1125-1138.
32. Woster PM. New therapies for malaria. Ann Rep Med Chem 2003;38:203-211.
33. Vennerstrom JL, Arbe-Barnes S, Brun R, Charman SA, Chiu FCK, Chollet J, Dong Y, Dorn A, Hunziker D, Matile H, McIntosh K, Padmanilayam M, Santo Tomas J, Scheurer C, Scorneaux B, et al. Identification of an antimalarial synthetic trioxolane drug development candidate. Nature 2004;430:900-904.
34. Wiesner J, Ortmann R, Jomaa H, Schlitzer M. New antimalarial drugs. Angew Chem Int Ed 2003;42:5274-5293.
35. Mehlin C. Structure-based drug discovery for Plasmodium falciparum. Comb Chem High Throughput Screen 2005;8:5-14.
36. Werbovetz KA. Target-based drug discovery for malaria, leishmaniasis, and trypanosomiasis. Curr Med Chem 2000;7:835-860.
37. Biagini GA, Ward SA, Bray PG. Malaria parasite transporters as a drug-delivery strategy. Trends Parasitol 2005;21:299-301.
38. Doerig C. Protein kinases as targets for anti-parasitic chemotherapy. Biochim Biophys Acta 2004;1697:155-168.
39. Fournet A, Munoz V. Natural products as trypanocidal, antileishmanial, and antimalarial drugs. CurrTop Med Chem 2002;2:1215-1237.
40. Carroll CD, Orlowski M. Screening aspartyl proteases with combinatorial libraries. Adv Exp Med Biol 1998;436 (Aspartic Proteinases):375-380.
41. Volk WA, Gebhardt BM, Hammarskjöld M-L, Kadner RJ. Essentials of medical microbiology. Philadelphia: Lippincott-Raven Publishers; 1996.
42. Khan SM, Waters AP. Malaria parasite transmission stages: An update. Trends Parasitol 2004;20:575-580.
43. Goldberg DE. Hemoglobin degradation in Plasmodium-infected red blood cells. Sem Cell Biol 1993;4:355-361.
44. Francis SE, Sullivan DJ Jr, Goldberg DE. Hemoglobin metabolism in the malaria parasite Plasmodium falciparum. Annu Rev Microbiol 1997;51:97-123.
45. Yayon A, Cabantchik ZI, Ginsburg H. Identification of the acidic compartment of Plasmodium falciparum-infected human erythrocytes as the target of the antimalarial drug chloroquine. EMBO J 1984;3:2695-2700.
46. 14C-labeled amino acids by the malaria [parasite] Plasmodium lophurea. IV. In vivo utilization of host-cell hemoglobin. Int J Biochem 1970;1:635-637.
47. Sherman IW. Amino acid metabolism and protein synthesis in malarial parasites. Bull WHO 1977;55:265-276.
48. Lew VL, Tiffert T, Ginsburg H. Excess hemoglobin digestion and the osmotic stability of Plasmodium falciparum-infected red blood cells. Blood 2003;101:4189-4194.
49. Bailly E, Jambou R, Savel J, Jaureguiberry G. Plasmodium falciparum: Differential sensitivity in vitro to E-64 (cysteine protease inhibitor) and Pepstatin A (aspartyl protease inhibitor). J Protozool 1992;39:593-599.
50. Francis SE, Gluzman IY, Oksman A, Knickerbocker A, Mueller R, Bryant ML, Sherman DR, Russell DG, Goldberg DE. Molecular characterization and inhibition of a Plasmodium falciparum aspartic hemoglobinase. EMBO J 1994;13:306-317.
51. Rosenthal PJ. Plasmodium falciparum: Effects of proteinase inhibitors on globin hydrolysis by cultured malaria parasites. Exp Parasitol 1995;80:272-281.
52. Olson JE, Lee GK, Semenov A, Rosenthal PJ. Antimalarial effects in mice of orally administered peptidyl cysteine protease inhibitors. Bioorg Med Chem 1999;7:633-638.
53. Goldberg DE, Slater AFG, Beavis R, Chait B, Cerami A, Henderson GB. Hemoglobin degradation in the human malaria pathogen Plasmodium falciparum: A catabolic pathway initiated by a specific aspartic protease. J Exp Med 1991;173:961-969.
54. Gluzman IY, Francis SE, Oksman A, Smith CE, Duffin KL, Goldberg DE. Order and Specificity of the Plasmodium falciparum hemoglobin degradation pathway. J Clin Invest 1994;93:1602-1608.
55. Dame JB, Reddy GR, Yowell CA, Dunn BM, Kay J, Berry C. Sequence, expression and modeled structure of an aspartic proteinase from the human malaria parasite Plasmodium falciparum. Mol Biochem Parasitol 1994;64:177-190.
56. Humphreys MJ, Moon RP, Klinder A, Fowler SD, Rupp K, Bur D, Ridley RG, Berry C. The aspartic proteinase from the rodent parasite Plasmodium berghei as a potential model for plasmepsins from the human malaria parasite, Plasmodium falciparum. FEBS Lett 1999;463:43-48.
57. Berry C, Humphreys MJ, Matharu P, Granger R, Horrocks P, Moon RP, Certa U, Ridley RG, Bur D, Kay J. A distinct member of the aspartic proteinase gene family from the human malaria parasite Plasmodium falciparum. FEBS Lett 1999;447:149-154.
58. Banerjee R, Liu J, Beatty W, Pelosof L, Klemba M, Goldberg DE. Four plasmepsins are active in the Plasmodium falciparum food vacuole, including a protease with an active-site histidine. Proc Natl Acad Sci USA 2002;99:990-995.
59. Salas F, Fichmann J, Lee GK, Scott MD, Rosenthal PJ. Functional expression of falcipain, a Plasmodium falciparum cysteine proteinase, supports its role as a malarial hemoglobinase. Infect Immun 1995;63:2120-2125.
60. Sijwali Puran S, Kato K, Seydel Karl B, Gut J, Lehman J, Klemba M, Goldberg Daniel E, Miller Louis H, Rosenthal Philip J. Plasmodium falciparum cysteine protease falcipain-1 is not essential in erythrocytic stage malaria parasites. Proc Natl Acad Sci USA 2004;101:8721-8726.
61. Shenai BR, Sijwali PS, Singh A, Rosenthal PJ. Characterization of native and recombinant falcipain-2, a principal trophozoite cysteine protease and essential hemoglobinase of Plasmodium falciparum. J Biol Chem 2000;275:29000-29010.
62. Sijwali PS, Rosenthal PJ. Gene disruption confirms a critical role for the cysteine protease falcipain-2 in hemoglobin hydrolysis by Plasmodium falciparum. Proc Natl Acad Sci USA 2004;101:4384-4389.
63. Sijwali PS, Shenai BR, Gut J, Singh A, Rosenthal PJ. Expression and characterization of the Plasmodium falciparum hemoglobinase falcipain-3. Biochem J 2001;360:481-489.
64. Eggleson KK, Duffin KL, Goldberg DE. Identification and characterization of falcilysin, a metallopeptidase involved in hemoglobin catabolism within the malaria parasite Plasmodium falciparum. J Biol Chem 1999;274:32411-32417.
65. Klemba M, Gluzman I, Goldberg DE. A Plasmodium falciparum dipeptidyl aminopeptidase I participates in vacuolar hemoglobin degradation. J Biol Chem 2004;279:43000-43007.
66. Coombs GH, Goldberg DE, Klemba M, Berry C, Kay J, Mottram JC. Aspartic proteases of Plasmodium falciparum and other parasitic protozoa as drug targets. Trends Parasitol 2001;17:532-537.
67. Gavigan CS, Dalton JP, Bell A. The role of aminopeptidases in haemoglobin degradation in Plasmodium falciparum-infected erythrocytes. Mol Biochem Parasitol 2001;117:37-48.
68. Dame JB, Yowell CA, Omara-Opyene L, Carlton JM, Cooper RA, Li T. Plasmepsin 4, the food vacuole aspartic proteinase found in all Plasmodium spp. infecting man. Mol Biochem Parasitol 2003;130:1-12.
69. Banerjee R, Francis SE, Goldberg DE. Food vacuole plasmepsins are processed at a conserved site by an acidic convertase activity in Plasmodium falciparum. Mol Biochem Parasitol 2003;129:157-165.
70. Klemba M, Beatty W, Gluzman I, Goldberg DE. Trafficking of plasmepsin II to the food vacuole of the malaria parasite Plasmodium falciparum. J Cell Biol 2004;164:47-56.
71. Francis SE, Banerjee R, Goldberg DE. Biosynthesis and maturation of the malaria aspartic hemoglobinases plasmepsins I and II. J Biol Chem 1997;272:14961-14968.
72. Le Bonniec S, Deregnaucourt C, Redeker V, Banerjee R, Grellier P, Goldberg DE, Schrevel J. Plasmepsin II, an acidic hemoglobinase from the Plasmodium falciparum food vacuole, is active at neutral pH on the host erythrocyte membrane skeleton. J Biol Chem 1999;274:14218-14223.
73. Wyatt DM, Berry C. Activity and inhibition of plasmepsin IV, a new aspartic proteinase from the malaria parasite, Plasmodium falciparum. FEBS Lett 2002;513:159-162.
74. Andreeva N, Bogdanovich P, Kashparov I, Popov M, Stengach M. Is histoaspartic protease a serine protease with a pepsin-like fold? Proteins: Struct Funct and Bioinf 2004;55:705-710.
75. Bjelic S, Aaqvist J. Computational prediction of structure, substrate binding mode, mechanism, and rate for a malaria protease with a novel type of active site. Biochemistry 2004;43:14521-14528.
76. Nezami A, Freire E. The integration of genomic and structural information in the development of high affinity plasmepsin inhibitors. Int J Parasitol 2002;32:1669-1676.
77. A search in the PDB for plasmepsins found 12 structures, and an additional 5 structures were processed or "on hold", as of August 2005.
78. Madabushi A, Chakraborty S, Fisher SZ, Clemente JC, Yowell C, Agbandje-McKenna M, Dame JB, Dunna BM, McKenna R. Crystallization and preliminary X-ray analysis of the aspartic protease plasmepsin 4 from the malarial parasite Plasmodium malariae. Acta Crystallograph Sect F Struct Biol Cryst Commun 2005;F61:228-231.
79. Silva AM, Lee AY, Erickson JW, Goldberg DE. Structural analysis of plasmepsin II: A comparison with human aspartic proteases. Adv Exp Med Biol 1998;436 (Aspartic Proteinases):363-373.
80. Bernstein NK, Cherney MM, Yowell CA, Dame JB, James MNG. Structural insights into the activation of P. vivax plasmepsin. J Mol Biol 2003;329:505-524.
81. Silva AM, Lee AY, Gulnik SV, Maier P, Collins J, Bhat TN, Collins PJ, Cachau RE, Luker KE, Gluzman IY, Francis SE, Oksman A, Goldberg DE, Erickson JW. Structure and inhibition of plasmepsin II, a hemoglobin-degrading enzyme from Plasmodium falciparum. Proc Natl Acad Sci USA 1996;93:10034-10039.
82. Rawlings Neil D, Tolle Dominic P, Barrett Alan J. MEROPS: The peptidase database. Nucleic Acids Res 2004;32 (Database issue):D160-D164.
83. Rawlings ND, Barrett AJ. Evolutionary families of peptidases. Biochem J 1993;290:205-218.
84. Davies DR. The structure and function of the aspartic proteinases. Annu Rev Biophys Biophys Chem 1990;19:189-215.
85. Fairlie DP, Tyndall JDA, Reid RC, Wong AK, Abbenante G, Scanlon MJ, March DR, Bergman DA, Chai CLL, Burkett BA. Conformational selection of inhibitors and substrates by proteolytic enzymes: Implications for drug design and polypeptide processing. J Med Chem 2000;43:1271-1281.
86. Schechter I, Berger A. On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun 1967;27:157-162.
87. Northrop DB. Follow the protons: A low-barrier hydrogen bond unifies the mechanisms of the aspartic proteases. Acc Chem Res 2001;34:790-797.
88. Dunn BM. Structure and mechanism of the pepsin-like family of aspartic peptidases. Chem Rev 2002;102:4431-4458.
89. Brik A, Wong C-H. HIV-1 protease: Mechanism and drug discovery. Org Biomol Chem 2003;1:5-14.
90. Prasad BVLS, Suguna K. Role of water molecules in the structure and function of aspartic proteinases. Acta Crystallogr D Biol Crystallogr 2002;D58:250-259.
91. Wolfenden R. Analog approaches to the structure of the transition state in enzyme reactions. Acc Chem Res 1972;5:10-18.
92. Lienhard GE. Enzymic catalysis and transition-state theory. Science 1973;180:149-154.
93. Dash C, Kulkarni A, Dunn B, Rao M. Aspartic peptidase inhibitors: Implications in drug development. Crit Rev Biochem Mol Biol 2003;38:89-119.
94. Babine RE, Bender SL. Molecular recognition of protein-ligand complexes: Applications to drug design. Chem Rev 1997;97:1359-1472.
95. Cooper JB. Aspartic proteinases in disease: A structural perspective. Curr Drug Targets 2002;3:155-173.
96. Moon RP, Tyas L, Certa U, Rupp K, Bur D, Jacquet C, Matile H, Loetscher H, Grueninger-Leitch F, Kay J, Dunn BM, Berry C, Ridley RG. Expression and characterization of plasmepsin I from Plasmodium falciparum. Eur J Biochem 1997;244:552-560.
97. Boss C, Richard-Bildstein S, Weller T, Fischli W, Meyer S, Binkert C. Inhibitors of the Plasmodium falciparum parasite aspartic protease plasmepsin II as potential antimalarial agents. Curr Med Chem 2003;10:883-907.
98. Westling J, Yowell CA, Majer P, Erickson JW, Dame JB, Dunn BM. Plasmodium falciparum, P. vivax, and P. malariae: A comparison of the active site properties of plasmepsins cloned and expressed from three different species of the malariae parasite. Exp Parasitol 1997;87:185-193.
99. Westling J, Cipullo P, Hung S-H, Saft H, Dame JB, Dunn BM. Active site specificity of plasmepsin II. Protein Sci 1999;8:2001-2009.
100. Gulnik SV, Suvorov LI, Majer P, Erickson JW. Sensitive fluorogenic substrates for plasmepsin 2. Protein Pept Lett 2000;7:219-223.
101. Dunn BM, Hung SH. The two sides of enzyme-substrate specificity: Lessons from the aspartic proteinases. Biochim Biophys Acta 2000;1477:231-240.
102. Li T, Yowell CA, Beyer BB, Hung S-H, Westling J, Lam MT, Dunn BM, Dame JB. Recombinant expression and enzymatic subsite characterization of plasmepsin 4 from the four Plasmodium species infecting man. Mol Biochem Parasitol 2004;135:101-109.
103. Beyer BB, Johnson JV, Chung AY, Li T, Madabushi A, Agbandje-McKenna M, McKenna R, Dame JB, Dunn BM. Active-site specificity of digestive aspartic peptidases from the four species of Plasmodium that infect humans using chromogenic combinatorial peptide libraries. Biochemistry 2005;44:1768-1779.
104. Siripurkpong P, Yuvaniyama J, Wilairat P, Goldberg DE. Active site contribution to specificity of the aspartic proteases plasmepsins I and II. J Biol Chem 2002;277:41009-41013.
105. Tyas L, Gluzman I, Moon RP, Rupp K, Westling J, Ridley RG, Kay J, Goldberg DE, Berry C. Naturally-occurring and recombinant forms of the aspartic proteinases plasmepsins I and II from the human malaria parasite Plasmodium falciparum. FEBS Lett 1999;454:210-214.
106. Istvan ES, Goldberg DE. Distal substrate interactions enhance plasmepsin activity. J Biol Chem 2005;280:6890-6896.
107. Moon RP, Bur D, Loetscher H, D'Arcy A, Tyas L, Oefner C, Grueninger-Leitch F, Mona D, Rupp K, Dorn A, Matile H, Certa U, Berry C, Kay J, Ridley RG. Studies on plasmepsins I and II from the malarial parasite Plasmodium falciparum and their exploitation as drug targets. Adv Exp Med Biol 1998;436 (Aspartic Proteinases):397-406, 392 plates.
108. Radding JA. Development of anti-malarial inhibitors of hemoglobinases. Annu Rep Med Chem 1999;34:159-168.
109. Berry C. Plasmepsins as antimalarial targets. Curr Opin Drug Di De 2000;3:624-629.
110. Eckstein Jens W. Malarial proteinases: A review of the recent patent literature. I Drugs 2002;5:342-348.
111. Abdel-Rahman HM, Kimura T, Hidaka K, Kiso A, Nezami A, Freire E, Hayashi Y, Kiso Y. Design of inhibitors against HIV, HTLV-I, and Plasmodium falciparum aspartic proteases. Biol Chem 2004;385:1035-1039.
112. Berry C. New targets for antimalarial therapy: The plasmepsins, malaria parasite proteases. Biochem Educ 1997;25:191-194.
113. Berry C. Proteases as drug targets for the treatment of malaria. Prot Infect Agents 1999;165-188.
114. Luker KE, Francis SE, Gluzman IY, Goldberg DE. Kinetic analysis of plasmepsins I and II, aspartic proteases of the Plasmodium falciparum digestive vacuole. Mol Biochem Parasitol 1996;79:71-78.
115. Nezami A, Kimura T, Hidaka K, Kiso A, Liu J, Kiso Y, Goldberg DE, Freire E. High-affinity inhibition of a family of Plasmodium falciparum proteases by a designed adaptive inhibitor. Biochemistry 2003;42:8459-8464.
116. Omara-Opyene AL, Moura PA, Sulsona CR, Bonilla JA, Yowell CA, Fujioka H, Fidock DA, Dame JB. Genetic disruption of the Plasmodium falciparum digestive vacuole plasmepsins demonstrates their functional redundancy. J Biol Chem 2004;279:54088-54096.
117. Liu J, Gluzman IY, Drew ME, Goldberg DE. The role of Plasmodium falciparum food vacuole plasmepsins. J BiolChem 2005;280:1432-1437.
118. Haque TS, Skillman AG, Lee CE, Habashita H, Gluzman IY, Ewing TJA, Goldberg DE, Kuntz ID, Ellman JA. Potent, low-molecular-weight non-peptide inhibitors of malarial aspartyl protease plasmepsin II. J Med Chem 1999;42:1428-1440.
119. Nezami A, Luque I, Kimura T, Kiso Y, Freire E. Identification and characterization of allophenylnorstatine-based inhibitors of plasmepsin II, an antimalarial target. Biochemistry 2002;41:2273-2280.
120. Asojo OA, Afonina E, Gulnik SV, Yu B, Erickson JW, Randad R, Medjahed D, Silva AM. Structures of Ser205 mutant plasmepsin II from Plasmodium falciparum at 1.8 Å in complex with the inhibitors rs367 and rs370. Acta Crystallogr D 2002;D58:2001-2008.
121. 2-symmetric malaria plasmepsin I and II inhibitors. Bioorg Med Chem 2003;11:1235-1246.
122. Bur D, Fischli W, Matile H, Ridley RG, Wostl W, (F. Hoffmann-La Roche A.-G., Switz.). assignee. Pharmaceutical preparations containing piperidine derivatives as antimalarials. Wo patent 9912532.1999.
123. 2-symmetric inhibitors of Plasmodium falciparum plasmepsin II: Synthesis and theoretical predictions. Bioorg Med Chem 2003;11:3723-3733.
124. Hua DH, Tamura M, Huang X, Stephany HA, Helfrich BA, Perchellet EM, Sperfslage BJ, Perchellet J-P, Jiang S, Kyle DE, Chiang PK. Syntheses and bioactivities of substituted 9,10-dihydro-9,10-[1,2]benzenoanthracene-1,4,5,8- tetrones. Unusual reactivities with amines. J Org Chem 2002;67:2907-2912.
125. Skinner-Adams TS, McCarthy JS, Gardiner DL, Hilton PM, Andrews KT. Antiretrovirals as antimalarial agents. J Infect Dis 2004;190:1998-2000.
126. Parikh S, Gut J, Istvan E, Goldberg Daniel E, Havlir Diane V, Rosenthal Philip J. Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors. Antimicrob Agents Chemother 2005;49:2983-2985.
127. Savarino A, Cauda R, Cassone A. Aspartic proteases of Plasmodium falciparum as the target of HIV-1 protease inhibitors. Comments J Infect Dis 2005;191:1381-1382.
128. Baldwin ET, Bhat TN, Gulnik S, Hosur MV, Sowder RC, Cachau RE, Collins J, Silva AM, Erickson JW. Crystal structures of native and inhibited forms of human cathepsin D: Implications for lysosomal targeting and drug design. Proc Natl Acad Sci USA 1993;90:6796-6800.
129. Molteni M, Pesenti C, Sani M, Volonterio A, Zanda M. Fluorinated peptidomimetics: Synthesis, conformational and biological features. J Fluorine Chem 2004;125:1735-1743.
130. Zanda M. Trifluoromethyl group: An effective xenobiotic function for peptide backbone modification. New J Chem 2004;28:1401-1411.
131. Johansson P-O, Chen Y, Belfrage AK, Blackman MJ, Kvarnstroem I, Jansson K, Vrang L, Hamelink E, Hallberg A, Rosenquist A, Samuelsson B. Design and synthesis of potent inhibitors of the malaria aspartyl proteases plasmepsin I and II. Use of solid-phase synthesis to explore novel statine motifs. J Med Chem 2004;47:3353-3366.
132. Johansson P-O, Lindberg J, Blackman MJ, Kvarnstroem I, Vrang L, Hamelink E, Hallberg A, Rosenquist SA, Samuelsson B. Design and synthesis of potent inhibitors of plasmepsin I and II: X-Ray crystal structure of inhibitor in complex with plasmepsin II. J Med Chem 2005;48:4400-4409.
133. Carroll CD, Patel H, Johnson TO, Guo T, Orlowski M, He Z-M, Cavallaro CL, Guo J, Oksman A, Gluzman IY, Connelly J, Chelsky D, Goldberg DE, Dolle RE. Identification of potent inhibitors of Plasmodium falciparum plasmepsin II from an encoded statine combinatorial library. Bioorg Med Chem Lett 1998;8:2315-2320.
134. Carroll CD, Johnson TO, Tao S, Lauri G, Orlowski M, Gluzman IY, Goldberg DE, Dolle RE. Evaluation of a structure-based statine cyclic diamino amide encoded combinatorial library against plasmepsin II and cathepsin D. Bioorg Med Chem Lett 1998;8:3203-3206.
135. Dolle RE, Guo J, O'Brien L, Jin Y, Piznik M, Bowman KJ, Li W, Egan WJ, Cavallaro CL, Roughton AL, Zhao W, Reader JC, Orlowski M, Jacob-Samuel B, Dilanni Carroll C. A statistical-based approach to assessing the fidelity of combinatorial libraries encoded with electrophoric molecular tags. Development and application of tag decode-assisted single bead LC/MS analysis. J Comb Chem 2000;2:716-731.
136. Dahlgren A, Kvarnstrom I, Vrang L, Hamelink E, Hallberg A, Rosenquist A, Samuelsson B. Solid-phase library synthesis of reversed-statine type inhibitors of the malarial aspartyl proteases plasmepsin I and II. Bioorg med Chem 2003;111:827-841.
137. Dahlgren A, Kvarnstrom I, Vrang L, Hamelink E, Hallberg A, Rosenquist A, Samuelsson B. New inhibitors of the malaria aspartyl proteases plasmepsin I and II. Bioorg Med Chem 2003;11:3423-3437.
138. Asojo OA, Gulnik SV, Afonina E, Yu B, Ellman JA, Haque TS, Silva AM. Novel uncomplexed and complexed structures of plasmepsin II, an aspartic protease from Plasmodium falciparum. J Mol Biol 2003;327:173-181.
139. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997;23:3-25.
140. Nöteberg D, Hamelink E, Hulten J, Wahlgren M, Vrang L, Samuelsson B, Hallberg A. Design and synthesis of plasmepsin I and plasmepsin II inhibitors with activity in Plasmodium falciparum-infected cultured human erythrocytes. J Med Chem 2003;46:734-746.
141. Nöteberg D, Schaal W, Hamelink E, Vrang L, Larhed M. High-speed optimization of inhibitors of the malarial proteases plasmepsin I and II. J Comb Chem 2003;5:456-464.
142. Muthas D, Nöteberg D, Sabnis YA, Hamelink E, Vrang L, Samuelsson B, Karlén A, Hallberg A. Synthesis, biological evaluation and modeling studies of inhibitors aimed at the malarial proteases plasmepsin I and II. Bioorg Med Chem 2005;13:5371-5390.
143. Kiso A, Hidaka K, Kimura T, Hayashi Y, Nezami A, Freire E, Kiso Y Search for substrate-based inhibitors fitting the S2′ space of malarial aspartic protease plasmepsin II. J Pept Sci 2004;10:641-647.
144. 2-symmetric P1/P1′-modified HIV-1 protease inhibitors. J Med Chem 1999;42:3835-3844.
145. Ersmark K, Feierberg I, Bjelic S, Hamelink E, Hackett F, Blackman MJ, Hulten J, Samuelsson B, Åqvist J, Hallberg A. Potent inhibitors of the Plasmodium falciparum enzymes plasmepsin I and II devoid of cathepsin D inhibitory activity. J Med Chem 2004;47:110-122.
146. Ersmark K, Nervall M, Hamelink E, Janka LK, Clemente JC, Dunn BM, Blackman MJ, Samuelsson B, Aqvist J, Hallberg A. Synthesis of malarial plasmepsin inhibitors and prediction of binding modes by molecular dynamics simulations. J Med Chem: ACS ASAP 2005;48:6090-6106.
147. Oefner C, Binggeli A, Breu V, Bur D, Clozel JP, D'Arcy A, Dorn A, Fischli W, Gruninger F, Guller R, Hirth G, Marki HP, Mathews S, Muller M, Ridley RG, et al. Renin inhibition by substituted piperidines: A novel paradigm for the inhibition of monomeric aspartic proteinases? Chem Biol 1999;6:127-131.
148. Bernstein NK, Cherney MM, Loetscher H, Ridley RG, James MNG. Crystal structure of the novel aspartic proteinase zymogen proplasmepsin II from Plasmodium falciparum. Nat Struct Biol 1999;6:32-37.
149. Carcache DA, Hoertner SR, Seiler P, Diederich F, Dorn A, Maerki HP, Binkert C, Bur D. Development of a new class of inhibitors for the malarial aspartic protease plasmepsin II based on a central 7-azabicyclo[2.2.1]heptane scaffold. Helv Chim Acta 2003;86:2173-2191.
150. Carcache DA, Hoertner SR, Bertogg A, Diederich F, Dorn A, Maerki HP, Binkert C, Bur D. A new class of inhibitors for the malarial aspartic protease plasmepsin II based on a central 11-azatricyclo[6.2.1.02,7]undeca-2,4,6-triene scaffold. Helv Chim Acta 2003;86:2192-2209.
151. Carcache DA, Hortner SR, Bertogg A, Binkert C, Bur D, Marki HP, Dorn A, Diederich F. De novo design, synthesis, and in vitro evaluation of a new class of nonpeptidic inhibitors of the malarial enzyme plasmepsin II. Chem Bio Chem 2002;3:1137-1141.
152. Mueller R, Huerzeler M, Boss C. Synthesis of plasmepsin II inhibitors-Potential antimalarial agents. Molecules 2003;8:556-564.
153. Boss C, Richard-Bildstein S, Furnari R, Bourgeois J-M, Corminboeuf O, Grisostomi C, Coppex L, Harris L, Prade L, Meyer S, Binkert C, Fischli W, Brun R, Weller T. Inhibitors of plasmepsin II-Potential antimalarial agents. Chimia 2004;58:634-639.
154. Prade L, Jones AF, Boss C, Richard-Bildstein S, Meyer S, Binkert C, Bur D. X-Ray structure of plasmepsin II complexed with a potent achiral inhibitor. J Biol Chem 2005;280:23837-23843.
155. Jiang S, Prigge ST, Wei L, Gao Y-E, Hudson TH, Gerena L, Dame JB, Kyle DE. New class of small nonpeptidyl compounds blocks Plasmodium falciparum development in vitro by inhibiting plasmepsins. Antimicrob Agents Chemother 2001;45:2577-2584.
156. Hu J-F, Schetz JA, Kelly M, Peng J-N, Ang KKH, Flotow H, Leong CY, Ng SB, Buss AD, Wilkins SP, Hamann MT. New antiinfective and human 5-HT2 receptor binding natural and semisynthetic compounds from the Jamaican sponge Smenospongia aurea. J Nat Prod 2002;65:476-480.
157. Ovenden SPB, Cao S, Leong C, Flotow H, Gupta MP, Buss AD, Butler MS. Spermine alkaloids from Albizia adinocephala with activity against Plasmodium falciparum plasmepsin II. Phytochemistry 2002;60:175-177.
158. Dell'Agli M, Parapini S, Basilico N, Verotta L, Taramelli D, Berry C, Bosisio E. In vitro studies on the mechanism of action of two compounds with antiplasmodial activity: Ellagic acid and 3,4,5-trimethoxyphenyl (6′-O-galloyl)-b-D-glucopyranoside. Planta Med 2003;69:162-164.
159. Subramanian E, Swan IDA, Liu M, Davies DR, Jenkins JA, Tickle IJ, Blundell TL. Homology among acid proteases: Comparison of crystal structures at 3. ANG. resolution of acid proteases from Rhizopus chinensis and Endothia parasitica. Proc Natl Acad Sci USA 1977;74:556-559.
160. Coburn CA, Stachel SJ, Li Y-M, Rush DM, Steele TG, Chen-Dodson E, Holloway MK, Xu M, Huang Q, Lai M-T, DiMuzio J, Crouthamel M-C, Shi X-P, Sardana V, Chen Z, et al. Identification of a small molecule nonpeptide active site b-secretase inhibitor that displays a nontraditional binding mode for aspartyl proteases. J Med Chem 2004;47:6117-6119.
161. Majer P, Collins J, Gulnik S, Erickson J, Pan W, Eissenstat MA, (United States Department of Health and Human Services, USA), assignee. Preparation of peptidomimetic inhibitors of cathepsin D and plasmepsins I and II. Wo patent 9730072. 1997.
162. Brinner KM, Kim JM, Habashita H, Gluzman IY, Goldberg DE, Ellman JA. Novel and potent anti-malarial agents. Bioorg Med Chem 2002;10:3649-3661.
163. Romeo S, Dell'Agli M, Parapini S, Rizzi L, Galli G, Mondani M, Sparatore A, Taramelli D, Bosisio E. Plasmepsin II inhibition and antiplasmodial activity of primaquine-statine 'double-drugs'. Bioorg Med Chem Lett 2004;14:2931-2934.
164. Eckstein JW, (Enanta Pharmaceuticals, Inc., USA), assignee. Preparation of linked plasmepsin and falcipain inhibitors for treatment of malaria. Wo patent 2001083433. 2001.
165. Choi CYH, Schneider EL, Kim JM, Gluzman IY, Goldberg DE, Ellman JA, Marletta MA. Interference with heme binding to histidine-rich protein-2 as an antimalarial strategy. Chem Biol 2002;9:881-889.
166. Semenov A, Olson JE, Rosenthal PJ. Antimalarial synergy of cysteine and aspartic protease inhibitors. Antimicrob Agents Chemotherapy 1998;42:2254-2258.
167. Tsuchiya Y, Hidaka K, Kiso A, Kimura T, Hayashi Y, Nezami A, Freire E, Kiso Y Evaluation of peptidomimetic inhibitors against malarial protease plasmepsin. Peptide Science 2005;41:527-530.
168. Bhattacharya G, Gerena L, Jiang S, Werbovetz KA. Activity of amidine-containing diphenylureas against P. falciparum. Lett Drug De Di 2005;2:162-164.